522 related articles for article (PubMed ID: 22429837)
1. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
2. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
3. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
4. Novel molecular targets for the therapy of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sternberg CN
Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
[TBL] [Abstract][Full Text] [Related]
5. New agents in the arsenal to fight castrate-resistant prostate cancer.
Ezzell EE; Chang KS; George BJ
Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
[TBL] [Abstract][Full Text] [Related]
6. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N
Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
[TBL] [Abstract][Full Text] [Related]
7. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
8. New treatment options for castration-resistant prostate cancer.
Simondsen K; Kolesar J
Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
[TBL] [Abstract][Full Text] [Related]
9. Castration-resistant prostate cancer: systemic therapy in 2012.
Maluf FC; Smaletz O; Herchenhorn D
Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
[TBL] [Abstract][Full Text] [Related]
10. New treatment options for castrate-resistant prostate cancer: a urology perspective.
Gomella LG; Gelpi F; Kelly WK
Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer.
Davda R; Hughes S; Jones R; Crabb SJ; Troup J; Payne H
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):376-85. PubMed ID: 26874654
[TBL] [Abstract][Full Text] [Related]
12. Novel and bone-targeted agents for CRPC.
Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
[TBL] [Abstract][Full Text] [Related]
13. Overview of the latest treatments for castration-resistant prostate cancer.
Bishr M; Saad F
Nat Rev Urol; 2013 Sep; 10(9):522-8. PubMed ID: 23797341
[TBL] [Abstract][Full Text] [Related]
14. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Pal SK; Sartor O
Maturitas; 2011 Feb; 68(2):103-5. PubMed ID: 21093995
[TBL] [Abstract][Full Text] [Related]
15. [Strategy in advanced castration-resistant prostate cancer].
Gross-Goupil M; Roca S; Pasticier G; Ravaud A
Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Sartor O; Michels RM; Massard C; de Bono JS
Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
[TBL] [Abstract][Full Text] [Related]
17. Treatment sequencing in metastatic castrate-resistant prostate cancer.
Sartor O; Gillessen S
Asian J Androl; 2014; 16(3):426-31. PubMed ID: 24675654
[TBL] [Abstract][Full Text] [Related]
18. New treatment options for patients with metastatic castration-resistant prostate cancer.
Higano CS
Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
Vasani D; Josephson DY; Carmichael C; Sartor O; Pal SK
Maturitas; 2011 Oct; 70(2):194-6. PubMed ID: 21831545
[TBL] [Abstract][Full Text] [Related]
20. [Management of metastatic castration-resistant prostate cancer following docetaxel].
Beuzeboc P; Ropert S; Goldwasser F; Zerbib M
Bull Cancer; 2012 Jul; 99 Suppl 1():S66-72. PubMed ID: 22516457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
